Impact of Pharmacogenetic Testing on Clozapine Treatment Efficacy in Patients with Treatment-Resistant Schizophrenia

被引:2
作者
Sanguesa, Estela [1 ]
Fernandez-Egea, Emilio [2 ,3 ]
Concha, Julia [1 ]
Garcia, Cristina B. [1 ]
Ribate, Maria Pilar [1 ]
机构
[1] Univ San Jorge, Fac Ciencias Salud, Villanueva Gallego, E-50830 Zaragoza, Spain
[2] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge CB21 5EF, England
[3] Univ Cambridge, Behav & Clin Neurosci Inst, Dept Psychiat, Cambridge CB2 0SZ, England
关键词
antipsychotics; pharmacodynamics; drug response; pharmacogenetic variants; genetic testing; treatment-resistant schizophrenia; 5-HT2A RECEPTOR GENE; CLINICAL-RESPONSE; SEROTONIN TRANSPORTER; CONSENSUS GUIDELINES; ALLELIC VARIATION; ASSOCIATION; POLYMORPHISMS; ABCB1;
D O I
10.3390/biomedicines12030597
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Managing schizophrenia with clozapine poses a significant challenge due to prevalent therapeutic failures. The increasing interest in personalized medicine underscores the importance of integrating pharmacogenetic information for effective pharmacotherapeutic monitoring in patients. The objective of this study was to explore the correlation between DRD2, HTR2A, SLC6A4, CYP1A2, and ABCB1 polymorphisms and clozapine response in 100 patients with Treatment-Resistant Schizophrenia. Different scales such as the Positive and Negative Syndrome Scale (PANSS), the Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS), the Global Assessment of Functioning Scale (GAF), the Brief Negative Symptom Scale (BNSS), and pharmacokinetic parameters were used to analyse the efficacy of the treatment. Patients who exclusively responded to clozapine compared to the patients with augmentation strategies exhibited distinctive features, such as lower doses, plasma levels, and presented less-pronounced symptomatology. Genetic associations were explored, highlighting SLC6A4, HTR2A, and the *1F/*1F polymorphism for the CYP1A2 gene.
引用
收藏
页数:11
相关论文
共 53 条
[1]   P-glycoprotein Inhibition for Optimal Drug Delivery [J].
Amin, Md. Lutful .
DRUG TARGET INSIGHTS, 2013, 7 :27-34
[2]   ASSOCIATION BETWEEN CLOZAPINE RESPONSE AND ALLELIC VARIATION IN 5HT(2A) RECEPTOR GENE [J].
ARRANZ, M ;
COLLIER, D ;
SODHI, M ;
BALL, D ;
ROBERTS, G ;
PRICE, J ;
SHAM, P ;
KERWIN, R .
LANCET, 1995, 346 (8970) :281-282
[3]   Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research [J].
Arranz, M. J. ;
de Leon, J. .
MOLECULAR PSYCHIATRY, 2007, 12 (08) :707-747
[4]  
Arranz MJ, 1996, NEUROSCI LETT, V217, P177, DOI 10.1016/0304-3940(96)13094-9
[5]   Pharmacogenetic prediction of clozapine response [J].
Arranz, MJ ;
Munro, J ;
Birkett, J ;
Bolonna, A ;
Mancama, D ;
Sodhi, M ;
Lesch, KP ;
Meyer, JFW ;
Sham, P ;
Collier, DA ;
Murray, RM ;
Kerwin, RW .
LANCET, 2000, 355 (9215) :1615-1616
[6]   Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine [J].
Arranz, MJ ;
Munro, J ;
Owen, MJ ;
Spurlock, G ;
Sham, PC ;
Zhao, J ;
Kirov, G ;
Collier, DA ;
Kerwin, RW .
MOLECULAR PSYCHIATRY, 1998, 3 (01) :61-66
[7]   The serotonin transporter and clozapine response [J].
Arranz, MJ ;
Bolonna, AA ;
Munro, J ;
Curtis, CJ ;
Collier, DA ;
Kerwin, RW .
MOLECULAR PSYCHIATRY, 2000, 5 (02) :124-125
[8]   THE ROLE OF THE SEROTONERGIC SYSTEM AT THE INTERFACE OF AGGRESSION AND SUICIDE [J].
Bortolato, M. ;
Pivac, N. ;
Seler, D. Muck ;
Perkovic, M. Nikolac ;
Pessia, M. ;
Di Giovanni, G. .
NEUROSCIENCE, 2013, 236 :160-185
[9]   The emergence, implementation, and future growth of pharmacogenomics in psychiatry: a narrative review [J].
Bousman, Chad A. ;
Al Maruf, Abdullah ;
Marques, Diogo Ferri ;
Brown, Lisa C. ;
Mueller, Daniel J. .
PSYCHOLOGICAL MEDICINE, 2023, 53 (16) :7983-7993
[10]  
Carbon M, 2014, DIALOGUES CLIN NEURO, V16, P505